Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

By J. Colombel, W. Sandborn, P. Rutgeerts, R. Enns, S. Hanauer, R. Panaccione, Stefan Schreiber, Daniel Byczkowski, Ju Li, J. Kent and 1 more. Gastroenterology, 2007

2,292 citations recorded by the source corpus.

Subfields: Genetics, Immunology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/742831db2da8205c8bb4cc59496de7c3812311c5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. W. Sandborn
2. Stefan Schreiber
3. S. Hanauer
4. Y. Chowers
5. S. Ben-Horin
6. Markus F. Neurath

In Immunology

1. Stefan Schreiber
2. W. Sandborn
3. S. Hanauer

In Rheumatology

1. Stefan Schreiber
2. W. Sandborn

Citations in the corpus

• Guidelines for the management of inflammatory bowel disease in adults (2011, result): “There was no statistical difference in GAIN between those failing IFX due to intolerance or as primary non-responders. The efficacy of maintenance therapy has been conclusively demonstrated by the CLASSIC-II and CHARM studies.”
• Certolizumab pegol for the treatment of Crohn’s disease (2011, background): “Attenuation of response among patients who respond to anti-TNF therapy with certolizumab pegol, infliximab and adalimumab, and then continue the same agent as maintenance therapy, occurs in approximately 60% of patients within 6 months [Colombel et al. 2007; Schreiber et al. 2007; Hanauer et al. 200”
• Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial (2007, background): “…the results from a large maintenance trial comparing adalimumab 40 mg every other week, adalimumab 40 mg weekly, and placebo (the CHARM study) 32 showed that adalimumab every other week and adalimumab weekly are equally effective in maintaining remission in patients with Crohn’s disease.”
• Review article: loss of response to anti‐TNF treatments in Crohn’s disease (2011, result): “munomodulators or other interventions to prevent loss of response to these agents, although in post hoc analysis of trials with these agents, patients on concomitant immunomodulators did not fare better than patients without.(3)”
• Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review (2009, background): “Interestingly, an effect of very similar magnitude has been observed for adalimumab in the CHARM trial ( Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease ) (”